CL2022000781A1 - Tratamientos cognitivos medicinales - Google Patents
Tratamientos cognitivos medicinalesInfo
- Publication number
- CL2022000781A1 CL2022000781A1 CL2022000781A CL2022000781A CL2022000781A1 CL 2022000781 A1 CL2022000781 A1 CL 2022000781A1 CL 2022000781 A CL2022000781 A CL 2022000781A CL 2022000781 A CL2022000781 A CL 2022000781A CL 2022000781 A1 CL2022000781 A1 CL 2022000781A1
- Authority
- CL
- Chile
- Prior art keywords
- medicinal
- healthy subject
- cognitive
- treatments
- cognitively healthy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019903681A AU2019903681A0 (en) | 2019-09-30 | Medicinal cognitive treatments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022000781A1 true CL2022000781A1 (es) | 2022-11-18 |
Family
ID=75336310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022000781A CL2022000781A1 (es) | 2019-09-30 | 2022-03-29 | Tratamientos cognitivos medicinales |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230000843A1 (https=) |
| EP (1) | EP4037684A4 (https=) |
| JP (1) | JP2022550221A (https=) |
| KR (1) | KR20220080116A (https=) |
| CN (1) | CN114761005A (https=) |
| CA (1) | CA3152902A1 (https=) |
| CL (1) | CL2022000781A1 (https=) |
| IL (1) | IL292739B1 (https=) |
| MX (1) | MX2022003845A (https=) |
| WO (1) | WO2021062472A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202523658A (zh) * | 2019-05-24 | 2025-06-16 | 美商賽吉醫療公司 | 化合物、組合物及使用方法 |
| WO2022115620A1 (en) * | 2020-11-25 | 2022-06-02 | Sage Therapeutics, Inc. | 4-fluoro-(4-(4-benzyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone derivatives and similar compounds as cyp46a1 inhibitors for the treatment of neurodegenerative disorders |
| CN120153257A (zh) * | 2022-10-07 | 2025-06-13 | 射线质医疗有限公司 | 用于11β-HSD1抑制剂治疗的受试者选择 |
| WO2025073002A1 (en) * | 2023-10-03 | 2025-04-10 | Actinogen Medical Limited | Tablet formulation |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8642621B2 (en) * | 2009-09-16 | 2014-02-04 | The University Of Edinburgh | (4-phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds and their use |
| AU2011247116B2 (en) * | 2010-04-29 | 2015-12-03 | The University Of Edinburgh | 3, 3 -disubstituted- ( 8 - aza - bicyclo [3.2.1] oct- 8 - yl) -[5- (1H - pyrazol - 4 -yl) -thiophen-3 -yl] methanones as inhibitors of 11 (beta) -HSD1 |
-
2020
- 2020-09-30 MX MX2022003845A patent/MX2022003845A/es unknown
- 2020-09-30 EP EP20870933.7A patent/EP4037684A4/en active Pending
- 2020-09-30 WO PCT/AU2020/051043 patent/WO2021062472A1/en not_active Ceased
- 2020-09-30 IL IL292739A patent/IL292739B1/en unknown
- 2020-09-30 CA CA3152902A patent/CA3152902A1/en active Pending
- 2020-09-30 JP JP2022544867A patent/JP2022550221A/ja active Pending
- 2020-09-30 US US17/764,922 patent/US20230000843A1/en active Pending
- 2020-09-30 CN CN202080082617.6A patent/CN114761005A/zh active Pending
- 2020-09-30 KR KR1020227014330A patent/KR20220080116A/ko not_active Ceased
-
2022
- 2022-03-29 CL CL2022000781A patent/CL2022000781A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021062472A1 (en) | 2021-04-08 |
| KR20220080116A (ko) | 2022-06-14 |
| MX2022003845A (es) | 2022-06-22 |
| CN114761005A (zh) | 2022-07-15 |
| IL292739B1 (en) | 2026-04-01 |
| AU2020359291A1 (en) | 2022-04-21 |
| IL292739A (en) | 2022-07-01 |
| EP4037684A4 (en) | 2023-11-01 |
| CA3152902A1 (en) | 2021-04-08 |
| EP4037684A1 (en) | 2022-08-10 |
| US20230000843A1 (en) | 2023-01-05 |
| JP2022550221A (ja) | 2022-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022000781A1 (es) | Tratamientos cognitivos medicinales | |
| PY2126213A (es) | Compuestos y métodos para el tratamiento de covid-19 | |
| CO2023000199A2 (es) | Péptidos funcionalizados como agentes antivirales | |
| CO2020015758A2 (es) | Compuestos de purinona y su uso en el tratamiento del cáncer | |
| MX2022000143A (es) | Metodos novedosos. | |
| ECSP22089498A (es) | Inhibidores de il4i1 y métodos de uso | |
| DOP2023000060A (es) | Inhibidores de la línea-1 para tratar enfermedades antecedentes de la invención | |
| MX2021014161A (es) | Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton. | |
| CL2021003312A1 (es) | Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma. | |
| MX2019004484A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia. | |
| AR119159A1 (es) | Tratamientos de angioedema | |
| PY1944026A (es) | Ácido ascórbico y compuestos quinona en combinación con un agente antiparasitario para tratar enfermedades parasitarias | |
| CO2025018532A2 (es) | Un método para el tratamiento de tumores sólidos con un conjugado anticuerpo-fármaco dirigido a claudina 18.2 | |
| CL2021003303A1 (es) | Tratamiento para sinucleinopatías. | |
| MX2025002228A (es) | Metodos para el tratamiento o la profilaxis de la endometriosis | |
| UY39593A (es) | Tratamiento para tumores sólidos malignos | |
| AR126393A1 (es) | Terapia combinada para el tratamiento de enfermedades hepáticas | |
| MX2022007854A (es) | Derivados del benzimidazol para el tratamiento y/o la prevención de enfermedades y trastornos mediados por el nlrp3. | |
| BR112022005980A2 (pt) | Método para prevenir e/ou tratar declínio cognitivo em um sujeito cognitivamente saudável, composto, e, uso de um composto | |
| MX2024007937A (es) | Tetrahidrobenzoazepinonas y analogos relacionados para la inhibicion de yap/taz-tead. | |
| CL2025000332A1 (es) | Tratamiento de la urticaria con inhibidores de jak. | |
| CL2024003468A1 (es) | Inhibidores de ripk1 y métodos de uso. | |
| CO2023010910A2 (es) | Tratamientos del síndrome de prader-willi | |
| CL2025003377A1 (es) | Tratamiento de afecciones inflamatorias que comprende imu-856. | |
| AR133890A1 (es) | INHIBICIÓN DE LA INTEGRINA a₅b₁ HUMANA |